Vaxart Inc (VXRT) - Total Assets
Based on the latest financial reports, Vaxart Inc (VXRT) holds total assets worth $180.06 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaxart Inc - Total Assets Trend (1985–2025)
This chart illustrates how Vaxart Inc's total assets have evolved over time, based on quarterly financial data. Also see VXRT market cap for the company's overall valuation and market capitalisation.
Vaxart Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vaxart Inc's total assets of $180.06 Million consist of 73.2% current assets and 26.9% non-current assets. Review Vaxart Inc (VXRT) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.9% |
| Accounts Receivable | $51.34 Million | 27.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.83 Million | 1.5% |
| Goodwill | $4.51 Million | 2.4% |
Asset Composition Trend (1985–2025)
This chart illustrates how Vaxart Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vaxart Inc (VXRT) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxart Inc's current assets represent 73.2% of total assets in 2025, an increase from 71.0% in 1985.
- Cash Position: Cash and equivalents constituted 28.9% of total assets in 2025, up from 15.0% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 8.0% in 1985.
- Asset Diversification: The largest asset category is accounts receivable at 27.6% of total assets.
Vaxart Inc Competitors by Total Assets
Key competitors of Vaxart Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Vaxart Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 0.64 | 14.83 |
| Quick Ratio | 1.71 | 0.64 | 14.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $54.86 Million | $-35.86 Million | $176.71 Million |
Vaxart Inc - Advanced Valuation Insights
This section examines the relationship between Vaxart Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.80 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | 11.8% |
| Total Assets | $186.08 Million |
| Market Capitalization | $118.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaxart Inc's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vaxart Inc's assets grew by 11.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vaxart Inc (1985–2025)
The table below shows the annual total assets of Vaxart Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $186.08 Million | +11.83% |
| 2024-12-31 | $166.39 Million | +81.19% |
| 2023-12-31 | $91.83 Million | -40.31% |
| 2022-12-31 | $153.85 Million | -30.44% |
| 2021-12-31 | $221.17 Million | +44.95% |
| 2020-12-31 | $152.58 Million | +312.03% |
| 2019-12-31 | $37.03 Million | +5.12% |
| 2018-12-31 | $35.23 Million | -12.15% |
| 2017-12-31 | $40.10 Million | -44.84% |
| 2016-12-31 | $72.70 Million | -8.44% |
| 2015-12-31 | $79.40 Million | -30.35% |
| 2014-12-31 | $114.00 Million | +32.87% |
| 2013-12-31 | $85.80 Million | +1.78% |
| 2012-12-31 | $84.30 Million | -13.95% |
| 2011-12-31 | $97.97 Million | -13.97% |
| 2010-12-31 | $113.87 Million | -13.29% |
| 2009-12-31 | $131.32 Million | -8.95% |
| 2008-12-31 | $144.22 Million | -39.55% |
| 2007-12-31 | $238.57 Million | -10.27% |
| 2006-12-31 | $265.88 Million | -19.27% |
| 2005-12-31 | $329.34 Million | -10.55% |
| 2004-12-31 | $368.17 Million | -4.94% |
| 2003-12-31 | $387.30 Million | +66.35% |
| 2002-12-31 | $232.82 Million | -24.97% |
| 2001-12-31 | $310.31 Million | +38.23% |
| 2000-12-31 | $224.49 Million | +4.61% |
| 1999-12-31 | $214.60 Million | -1.69% |
| 1998-12-31 | $218.30 Million | -3.36% |
| 1997-12-31 | $225.90 Million | +11.78% |
| 1996-12-31 | $202.10 Million | +46.45% |
| 1995-12-31 | $138.00 Million | +47.12% |
| 1994-12-31 | $93.80 Million | +77.32% |
| 1993-12-31 | $52.90 Million | +11.37% |
| 1992-12-31 | $47.50 Million | +78.57% |
| 1991-12-31 | $26.60 Million | +12.24% |
| 1990-12-31 | $23.70 Million | -2.87% |
| 1989-12-31 | $24.40 Million | +16.75% |
| 1988-12-31 | $20.90 Million | +53.68% |
| 1987-12-31 | $13.60 Million | +1.49% |
| 1986-12-31 | $13.40 Million | +34.00% |
| 1985-12-31 | $10.00 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more